The development of resistance of HIV-1 to zalcitabine.
Craig
C
C
Moyle
G
G
D000596:Amino Acids / Q000032:analysis; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D016049:Didanosine / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D014644:Genetic Variation; D015658:HIV Infections / Q000188:drug therapy*; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors / Q000737:chemistry; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008958:Models, Molecular; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D016047:Zalcitabine / Q000627:therapeutic use*
D000596:Amino Acids; D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D016047:Zalcitabine; D054303:HIV Reverse Transcriptase; D016049:Didanosine